ArriVent BioPharma, Inc. SEC filings AVBP
ArriVent BioPharma, Inc. has 160 filings in SEC EDGAR's recent list, going back to Jun 23, 2021. Its latest annual report, Form ARS, was filed on Apr 28, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 12, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 26, 2026 (regulation fd disclosure, other events). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Nov 5, 2026 | — |
| 4 | Insider transaction | Nov 2, 2026 | Oct 30, 2026 |
| SCHEDULE 13G | Ownership over 5% (passive) | Oct 13, 2026 | — |
| SCHEDULE 13D/A | Amended ownership over 5% (active) | Oct 8, 2026 | — |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Jul 27, 2026 | — |
| 4 | Insider transaction | Jun 22, 2026 | Jun 18, 2026 |
| 4 | Insider transaction | Jun 22, 2026 | Jun 18, 2026 |
| 4 | Insider transaction | Jun 22, 2026 | Jun 18, 2026 |
| 4 | Insider transaction | Jun 22, 2026 | Jun 18, 2026 |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | May 6, 2026 | — |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Mar 5, 2026 | — |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Feb 17, 2026 | — |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Feb 17, 2026 | — |
| 4 | Insider transaction | Feb 4, 2026 | Feb 2, 2026 |
| 4 | Insider transaction | Feb 4, 2026 | Feb 2, 2026 |
| 4 | Insider transaction | Feb 4, 2026 | Feb 2, 2026 |
| 4 | Insider transaction | Feb 4, 2026 | Feb 2, 2026 |
| 4 | Insider transaction | Feb 4, 2026 | Feb 2, 2026 |
| 4 | Insider transaction | Feb 3, 2026 | Dec 10, 2025 |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Jan 30, 2026 | — |
| SCHEDULE 13G | Ownership over 5% (passive) | Jan 21, 2026 | — |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Nov 14, 2025 | — |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Nov 5, 2025 | — |
| SCHEDULE 13G | Ownership over 5% (passive) | Oct 30, 2025 | — |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Oct 17, 2025 | — |
| SCHEDULE 13G | Ownership over 5% (passive) | Oct 15, 2025 | — |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Aug 14, 2025 | — |
| SCHEDULE 13D/A | Amended ownership over 5% (active) | Aug 13, 2025 | — |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Aug 13, 2025 | — |
| SCHEDULE 13G | Ownership over 5% (passive) | Aug 13, 2025 | — |
| 4 | Insider transaction | Jul 15, 2025 | Jul 11, 2025 |
| 4 | Insider transaction | Jun 20, 2025 | Jun 18, 2025 |
| 4 | Insider transaction | Jun 20, 2025 | Jun 18, 2025 |
| 4 | Insider transaction | Jun 20, 2025 | Jun 18, 2025 |
| 4 | Insider transaction | Jun 20, 2025 | Jun 18, 2025 |
| SCHEDULE 13G | Ownership over 5% (passive) | May 15, 2025 | — |
| 4 | Insider transaction | Apr 29, 2025 | Apr 28, 2025 |
| 3 | Initial insider ownership | Apr 29, 2025 | Apr 28, 2025 |
| SCHEDULE 13G | Ownership over 5% (passive) | Feb 14, 2025 | — |
| 4 | Insider transaction | Feb 14, 2025 | Feb 3, 2025 |
| 4 | Insider transaction | Feb 14, 2025 | Feb 3, 2025 |
| 4 | Insider transaction | Feb 14, 2025 | Feb 3, 2025 |
| 4 | Insider transaction | Feb 14, 2025 | Feb 3, 2025 |
| 4 | Insider transaction | Feb 14, 2025 | Feb 3, 2025 |
| SC 13G | Ownership over 5% (passive) | Dec 4, 2024 | — |
| SC 13G | Ownership over 5% (passive) | Nov 14, 2024 | — |
| SC 13G | Ownership over 5% (passive) | Nov 12, 2024 | — |
| SC 13G | Ownership over 5% (passive) | Nov 12, 2024 | — |
| SC 13G | Ownership over 5% (passive) | Nov 8, 2024 | — |
| SC 13G | Ownership over 5% (passive) | Oct 24, 2024 | — |
| SC 13G | Ownership over 5% (passive) | Oct 11, 2024 | — |
| 4 | Insider transaction | Sep 23, 2024 | Sep 19, 2024 |
| 4 | Insider transaction | May 20, 2024 | May 16, 2024 |
| 3 | Initial insider ownership | May 20, 2024 | May 16, 2024 |
| 4 | Insider transaction | Apr 23, 2024 | Apr 22, 2024 |
| 3 | Initial insider ownership | Apr 23, 2024 | Apr 20, 2024 |
| SC 13G | Ownership over 5% (passive) | Feb 13, 2024 | — |
| SC 13D | Ownership over 5% (active) | Feb 5, 2024 | — |
| 4 | Insider transaction | Feb 1, 2024 | Jan 30, 2024 |
| 4 | Insider transaction | Jan 31, 2024 | Jan 30, 2024 |
| 4 | Insider transaction | Jan 31, 2024 | Jan 30, 2024 |
| 4 | Insider transaction | Jan 31, 2024 | Jan 30, 2024 |
| 4 | Insider transaction | Jan 29, 2024 | Jan 25, 2024 |
| 4 | Insider transaction | Jan 29, 2024 | Jan 25, 2024 |
| 3 | Initial insider ownership | Jan 25, 2024 | Jan 25, 2024 |
| 3 | Initial insider ownership | Jan 25, 2024 | Jan 25, 2024 |
| 3 | Initial insider ownership | Jan 25, 2024 | Jan 25, 2024 |
| 3 | Initial insider ownership | Jan 25, 2024 | Jan 25, 2024 |
| 3 | Initial insider ownership | Jan 25, 2024 | Jan 25, 2024 |
| 3 | Initial insider ownership | Jan 25, 2024 | Jan 25, 2024 |
| 3 | Initial insider ownership | Jan 25, 2024 | Jan 25, 2024 |
| 3 | Initial insider ownership | Jan 25, 2024 | Jan 25, 2024 |
| 3 | Initial insider ownership | Jan 25, 2024 | Jan 25, 2024 |
| 3 | Initial insider ownership | Jan 25, 2024 | Jan 25, 2024 |
| 3 | Initial insider ownership | Jan 25, 2024 | Jan 25, 2024 |
Showing 75 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- AVBP (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Newtown Square, PA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1868279
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.